IL113851A - Continuous method of grinding pharmaceutical substances - Google Patents

Continuous method of grinding pharmaceutical substances

Info

Publication number
IL113851A
IL113851A IL11385195A IL11385195A IL113851A IL 113851 A IL113851 A IL 113851A IL 11385195 A IL11385195 A IL 11385195A IL 11385195 A IL11385195 A IL 11385195A IL 113851 A IL113851 A IL 113851A
Authority
IL
Israel
Prior art keywords
agent
grinding media
milling chamber
particle size
grinding
Prior art date
Application number
IL11385195A
Other languages
English (en)
Other versions
IL113851A0 (en
Original Assignee
Nanosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems Llc filed Critical Nanosystems Llc
Publication of IL113851A0 publication Critical patent/IL113851A0/xx
Publication of IL113851A publication Critical patent/IL113851A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/888—Shaping or removal of materials, e.g. etching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crushing And Pulverization Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Disintegrating Or Milling (AREA)
IL11385195A 1994-05-25 1995-05-25 Continuous method of grinding pharmaceutical substances IL113851A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/249,787 US5718388A (en) 1994-05-25 1994-05-25 Continuous method of grinding pharmaceutical substances

Publications (2)

Publication Number Publication Date
IL113851A0 IL113851A0 (en) 1995-08-31
IL113851A true IL113851A (en) 1999-12-22

Family

ID=22944996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11385195A IL113851A (en) 1994-05-25 1995-05-25 Continuous method of grinding pharmaceutical substances

Country Status (14)

Country Link
US (1) US5718388A (fr)
EP (1) EP0804161B1 (fr)
JP (1) JP3607294B2 (fr)
AT (1) ATE208191T1 (fr)
AU (1) AU2476195A (fr)
CA (1) CA2190134C (fr)
DE (1) DE69523781T2 (fr)
DK (1) DK0804161T3 (fr)
ES (1) ES2165913T3 (fr)
IL (1) IL113851A (fr)
MY (1) MY113569A (fr)
PT (1) PT804161E (fr)
TW (1) TW460297B (fr)
WO (1) WO1995031973A1 (fr)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6000646A (en) * 1998-03-16 1999-12-14 Ranne; Bethyl H. Double barrel media mill for grinding and dispersing particulate matter and pigment for paint, coatings, ink and other fluid pigment vehicles
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
AU5300000A (en) * 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US20040026546A1 (en) 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7100851B2 (en) * 2001-04-27 2006-09-05 Kansai Paint Co., Ltd. Method and apparatus for dispersing pigment in liquid medium
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US6722699B2 (en) * 2001-08-02 2004-04-20 Eastman Kodak Company Authentication using near-field optical imaging
US8403367B2 (en) 2001-08-02 2013-03-26 Eastman Kodak Company Authentication using near-field optical imaging
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
CA2465793A1 (fr) * 2001-11-07 2003-05-15 Taffy Williams Procedes d'imagerie vasculaire comprenant l'utilisation d'agents de contraste nanoparticulaires
JP2005513080A (ja) 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
EP1471887B1 (fr) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Compositions nanoparticulaires a stabilisateur superficiel de lysozyme
US6699963B2 (en) 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
WO2003080023A2 (fr) * 2002-03-20 2003-10-02 Elan Pharma International Limited Formes posologiques a dissolution rapide presentant une friabilite reduite
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003082213A2 (fr) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions et procedes de distribution d'agents pharmaceutiquement actifs au moyen de nanoparticules
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP1494649B1 (fr) 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Preparations de megestrol nanoparticulaires
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
EP2283864A1 (fr) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Composition liquide contenant des nanoparticules stabilisées d'une substance active
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
CN101119795B (zh) * 2002-10-09 2011-02-23 诺维信公司 一种改进粒子组合物的方法
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
CA2504610C (fr) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Formes posologiques solides a desintegration rapide non friables et comprenant du pullulane
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (fr) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Broyage de quantites de composes candidats nanoparticulaires de l'ordre du microgramme
JP2006515026A (ja) 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004078162A1 (fr) * 2003-01-31 2004-09-16 Elan Pharma International Ltd. Formulations contenant des nanoparticules de topiramate
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2005013337A2 (fr) * 2003-03-06 2005-02-10 Rensselaer Polytechnic Institute Production rapide de nanoparticules a partir de solides en vrac a temperature ambiante
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (fr) * 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1626742A1 (fr) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilisation de dispersions d'agents actifs particulaires au moyen de rayons gamma
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US7618181B2 (en) * 2003-10-23 2009-11-17 Kansai Paint Co., Ltd. Method for dispersing pigment in liquid medium
EP1686962B9 (fr) * 2003-11-05 2012-10-03 Elan Pharma International Limited Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
EP1621200A1 (fr) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate
CN101106972A (zh) 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (fr) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Formulations renfermant des nanoparticules de tacrolimus
WO2006069098A1 (fr) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Formulations de la bicalutamide nanoparticulaire
EP1830902A2 (fr) * 2004-12-30 2007-09-12 Cinvention Ag Ensemble comprenant un agent produisant un signal, un implant et un medicament
EP1830824B1 (fr) * 2004-12-31 2016-01-13 Iceutica Pty Ltd. Composition de nanoparticules et procedes de synthese de cette derniere
EP1835890A2 (fr) * 2005-01-06 2007-09-26 Elan Pharma International Limited Formulations nanoparticulaires de candesartan
CA2591942A1 (fr) * 2005-01-13 2006-07-20 Cinvention Ag Materiaux composites contenant des nanoparticules de carbone
WO2006077256A1 (fr) * 2005-01-24 2006-07-27 Cinvention Ag Materiaux composites contenant du metal
KR20070112164A (ko) 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
WO2006099121A2 (fr) * 2005-03-10 2006-09-21 Elan Pharma International Limited Preparations de finasteride, de dutasteride et de chlorhydrate de tamsulosine nanoparticulaires et de melanges de ceux-ci
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
EA200702019A1 (ru) * 2005-03-18 2008-02-28 Синвеншен Аг Способ изготовления пористых спечённых металлсодержащих материалов
WO2006102494A2 (fr) * 2005-03-23 2006-09-28 Elan Pharma International Limited Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
AU2006235478B2 (en) * 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
CA2609296A1 (fr) * 2005-05-16 2006-11-16 Elan Pharma International Limited Compositions a nanoparticules et liberation controlee comportant une cephalosporine
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
WO2006133045A1 (fr) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Préparations de benidipine nanoparticulaire
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2008073068A1 (fr) 2005-06-08 2008-06-19 Elan Pharma International Limited Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
CA2612384A1 (fr) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Formulations d'azelnidipine nanoparticulaire
WO2007003516A2 (fr) * 2005-07-01 2007-01-11 Cinvention Ag Dispositifs medicaux comprenant une matiere composite reticulee
AU2006265193A1 (en) * 2005-07-01 2007-01-11 Cinvention Ag Process for the production of porous reticulated composite materials
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
CA2622758A1 (fr) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Formulations aripiprazoliques nanoparticulaires
JP2009511727A (ja) * 2005-10-18 2009-03-19 シンベンション アーゲー 熱硬化粒子及びその製造方法
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
CA2635531C (fr) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Derives d'acides amines multicycliques et procedes d'utilisation de ceux-ci
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
EP2001439A2 (fr) * 2006-03-07 2008-12-17 Novavax, Inc. Emulsions nano-structurees des agents actifs mauvais soluble et leurs procedes de fabrication
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CN101646402A (zh) * 2007-01-19 2010-02-10 金文申有限公司 用粉末模塑法制成的多孔、不可降解植入物
WO2008104599A1 (fr) * 2007-02-28 2008-09-04 Cinvention Ag Sac à grande surface pour système de culture
AU2008220791A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with surface increasing substrate
CA2677699A1 (fr) * 2007-02-28 2008-09-04 Cinvention Ag Systeme de culture a surface elevee
US20080206734A1 (en) * 2007-02-28 2008-08-28 Cinvention Ag High surface cultivation system with filler
AU2009225719A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
WO2010096558A1 (fr) 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Utilisation d'un copolymère bifonctionnel pour des applications ophtalmiques et autres topiques et locales
WO2010099508A1 (fr) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
EP3167875A1 (fr) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
ES2699077T3 (es) 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
AU2010261510A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
EP2442794A1 (fr) 2009-06-19 2012-04-25 Nanoform Hungary Ltd. Compositions nanoparticulaires de telmisartan et procédé de préparation de celles-ci
CN102711749A (zh) 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
CN102753168A (zh) 2010-02-10 2012-10-24 莱西肯医药有限公司 用于治疗转移性骨病的色氨酸羟化酶抑制剂
ES2689520T3 (es) 2010-04-23 2018-11-14 Kempharm, Inc. Formulación terapéutica para reducir los efectos secundarios de fármacos
WO2011146583A2 (fr) 2010-05-19 2011-11-24 Elan Pharma International Limited Formulations de cinacalcet nanoparticulaire
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
EP2618818A4 (fr) 2010-09-22 2014-10-29 Map Pharmaceuticals Inc Particules de corticostéroïdes et leur procédé de production
DE102010052656B4 (de) * 2010-11-26 2025-08-21 Netzsch-Feinmahltechnik Gmbh Hydraulische mahlkugelzu- und abfuhr für rührwerkskugelmühlen
PT2651357T (pt) 2010-12-16 2020-06-17 Sunovion Pharmaceuticals Inc Películas sublinguais
WO2013059676A1 (fr) 2011-10-21 2013-04-25 Subhash Desai Compositions pour la réduction d'effets secondaires
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
NZ629438A (en) * 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
WO2013148978A1 (fr) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Méthodes et compositions pour le traitement de l'entérocolite nécrosante
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
EP2956138B1 (fr) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016508447A (ja) * 2013-02-28 2016-03-22 サン・ケミカル・コーポレーション 連続的微細メディア含有粉砕プロセス
JP6063090B2 (ja) 2013-06-28 2017-01-18 レクサン ファーマシューティカルズ インコーポレイテッド ナノ粒子状組成物およびピペラジン化合物の製剤
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015071841A1 (fr) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
US20150343453A1 (en) * 2014-05-28 2015-12-03 NanoCentrix L.L.C. Fluid energy media mill system and method
RU2705376C2 (ru) 2014-08-18 2019-11-07 Алкермес Фарма Айэленд Лимитед Композиции пролекарства арипипразола
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EP4578461A3 (fr) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Méthodes de traitement de la maladie de parkinson par administration d'apomorphine à une muqueuse buccale
CA2984421C (fr) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Analogues de nucleosides a utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CA3014788A1 (fr) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions de multiples promedicaments a base d'aripiprazole
EP3481387A4 (fr) 2016-08-11 2020-04-08 Ovid Therapeutics Inc Methodes et compositions pour le traitement de troubles épileptiques
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (fr) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP6328860B1 (ja) 2016-09-13 2018-05-23 協和発酵キリン株式会社 医薬組成物
CN111971284A (zh) 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
EP3840754A4 (fr) 2018-08-23 2022-09-14 Sunovion Pharmaceuticals Inc. Sels d'addition d'acides d'apomorphine, compositions pharmaceutiques en contenant et leurs procédés d'utilisation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
JP7754799B2 (ja) 2019-08-05 2025-10-15 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
US20230339880A1 (en) 2019-10-11 2023-10-26 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
WO2021113834A1 (fr) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone destinée à être utilisée dans le traitement du complexe de la sclérose tubéreuse
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
JP2022052396A (ja) * 2020-09-23 2022-04-04 株式会社リコー 分散液の製造方法及び製造装置
CN112427096B (zh) * 2020-10-19 2022-01-28 上海旭军机械有限公司 一种纳米材料的研磨设备
CN116408192B (zh) * 2021-12-29 2026-02-17 南方科技大学 一种表界面调控法制备微纳米碳颗粒的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595117A (en) * 1950-03-08 1952-04-29 Smidth & Co As F L Method and apparatus for grinding
ES293103A1 (es) * 1962-11-12 1964-03-16 Aziende Colori Naz Affini Acna S P A Procedimiento para la preparación de quinacridona en forma de pigmento
US3713593A (en) * 1970-08-11 1973-01-30 Freeport Sulphur Co Fine media milling process
SU514627A1 (ru) * 1972-07-19 1976-05-25 Институт Биохимии И Физиологии Микроорганизмов Ан Ссср Дезинтегратор дл микроорганизмов
US4860957A (en) * 1988-03-29 1989-08-29 Lidstroem Lars Treatment of middlings
JPH02132162A (ja) * 1988-11-11 1990-05-21 Showa Shell Sekiyu Kk 微小ジルコニア焼成ボールによる顔料の分散方法
US5174512A (en) * 1988-12-16 1992-12-29 Snamprogetti S.P.A. Grinding process and a continuous high-capacity micronizing mill for its implementation
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
JPH04166246A (ja) * 1990-10-31 1992-06-12 Matsushita Electric Ind Co Ltd 媒体撹拌ミル及び粉砕方法
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
JPH05253509A (ja) * 1991-05-08 1993-10-05 Fuaimatetsuku:Kk 流通式媒体攪拌超微粉砕機
JPH05253512A (ja) * 1992-03-11 1993-10-05 Chuo Kakoki Kk 粉粒体又はスラリーの処理用媒体
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances

Also Published As

Publication number Publication date
DK0804161T3 (da) 2002-03-04
JP3607294B2 (ja) 2005-01-05
IL113851A0 (en) 1995-08-31
DE69523781D1 (de) 2001-12-13
CA2190134C (fr) 2005-03-08
PT804161E (pt) 2002-04-29
MY113569A (en) 2002-04-30
DE69523781T2 (de) 2002-06-13
TW460297B (en) 2001-10-21
JPH10500593A (ja) 1998-01-20
EP0804161A1 (fr) 1997-11-05
AU2476195A (en) 1995-12-18
ES2165913T3 (es) 2002-04-01
ATE208191T1 (de) 2001-11-15
EP0804161B1 (fr) 2001-11-07
US5718388A (en) 1998-02-17
WO1995031973A1 (fr) 1995-11-30
CA2190134A1 (fr) 1995-11-30

Similar Documents

Publication Publication Date Title
IL113851A (en) Continuous method of grinding pharmaceutical substances
AU2550195A (en) Method of grinding pharmaceutical substances
CA2182786A1 (fr) Procede pour la fabrication de particules ou de poudres
WO2002045691A3 (fr) Procede de broyage a echelle de laboratoire
PL323444A1 (en) Method of and apparatus for elestrostatically charging particles suspended in fluid gaseous medium and separating them therefrom
CA2237310A1 (fr) Procede de separation et de recuperation de constituants de tapis mis au rebut
ATE188391T1 (de) Methode und vorrichtung zur flüssigkeitschromatographie
AU2800395A (en) Method and apparatus for the formation of particles
CA2166301A1 (fr) Methode et appareil pour la formation de particules
CA2056422A1 (fr) Separateur electrostatique
PL307354A1 (en) Treating apparatus
IN171515B (fr)
KR960700819A (ko) 지르코늄 실리케이트 연마 매체 및 분쇄 방법(zirconium silicate grinding medium and method of milling)
DE2813735A1 (de) Verfahren zur entstaubung von gasen
JP3924733B2 (ja) 湿式媒体分散装置
ENDO et al. Flow Rates and Pressure Drops Through the Packed Beds of Surface Treated Particles
HU903176D0 (en) Liquid filter for separation of solid impurities, agglomerated grains of suspensions and other particles formed by settling out in liquids
JPS59154149A (ja) 固体粒子の粉砕法
HUT60643A (en) Method for filtering the dust content of air and air-filtering insert
HK1001541A1 (en) Process and plant for separating husks from malt
CA2262746A1 (fr) Procede et appareil de separation d'un solvant d'avec un courant de solvant et de petrole desasphalte

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired